The latest report by IMARC Group, titled "United States Diabetes Market Size, Share, Trends and Forecast by Segment and Distribution Channel, 2026-2034", offers a comprehensive analysis of the industry, which comprises insights on the United States diabetes market. The report also includes competitor and regional analysis.

United States Diabetes Market Size Overview and Growth Forecast (2026–2034)

The United States diabetes market size grew from USD 31.09 Billion in 2025 to USD 31.96 Billion in 2026 and is projected to reach USD 39.80 Billion by 2034, growing at a CAGR of 2.78% during 2026–2034. Market growth is supported by the high prevalence of diabetes, rising obesity rates, growing adoption of advanced therapies and technologies, and increasing healthcare expenditure. As manufacturers continue to introduce innovative treatment options tailored to changing patient needs, the United States diabetes market growth is expected to remain steady over the forecast period.

Key Market Statistics at a Glance

Base Year: 2025

Historical Years: 2020–2025

Forecast Period: 2026–2034

Market Size (2025): USD 31.09 Billion

Market Size (2026): USD 31.96 Billion

Projected Size (2034): USD 39.80 Billion

Growth Rate: CAGR of 2.78%

Explore Growth Opportunities in the United States Diabetes Market Grab Your Sample Report for Evaluation:

https://www.imarcgroup.com/us-diabetes-market/requestsample

Key Factors Driving the United States Diabetes Market

Growing awareness of diabetes management and early disease detection is one of the major factors supporting the United States diabetes market growth. More than 40 million Americans, or around 12% of the population, are living with diabetes, driving strong demand for insulin therapies, oral antidiabetics, and continuous glucose monitoring solutions. The expansion of GLP-1 receptor agonist therapies, supportive reimbursement frameworks such as the Inflation Reduction Act's insulin cost cap, and integration of digital health platforms are also helping companies reach a wider patient base. In addition, rising demand for personalized and technology-driven treatment options continues to strengthen the United States diabetes market share across different therapy categories.

United States Diabetes Market Segmentation and Industry Trends

The United States diabetes market analysis covers multiple treatment segments, distribution channels, and patient segments. Insulin continues to represent the leading segment, while oral antidiabetics are also witnessing healthy demand supported by SGLT-2 inhibitor growth. Among the leading United States diabetes market trends are the growing adoption of GLP-1 and dual GIP/GLP-1 agonists as first-line therapy, expansion of over-the-counter continuous glucose monitoring devices, increasing use of biosimilar insulin, and higher demand for personalized diabetes medicine. These trends are encouraging manufacturers to expand their product portfolios and invest in product innovation.

Challenges and Opportunities in the United States Diabetes Market

The market faces challenges such as drug price negotiation compression under the Inflation Reduction Act, biosimilar insulin pricing pressure on branded revenues, and manufacturing capacity constraints for GLP-1 therapies. However, these factors are encouraging companies to improve supply chain efficiency and focus on value-added treatment options. There are also significant opportunities for companies offering obesity-adjacent GLP-1 therapies, once-weekly basal insulin products, and oral GLP-1 agonist formulations. As patient preferences continue to evolve, businesses investing in innovation, digital health integration, and broader insurance access are well positioned to benefit from the continued United States diabetes market growth.

Future Outlook: What's Next for the United States Diabetes Market?

The outlook for the United States diabetes market remains positive, supported by product innovation, digital health integration, and changing patient care models. Future United States diabetes market trends are expected to include greater adoption of once-weekly insulin therapies, expansion of oral GLP-1 agonists, wider access to over-the-counter continuous glucose monitoring, and continued growth of e-commerce and tele-pharmacy channels. Companies that focus on innovation, affordability, and strong patient engagement will be well placed to expand their United States diabetes market share and capitalize on long-term growth opportunities through 2034.

United States Diabetes Market Segmentation:

Segment Insights:

•        Insulin

•        Oral Antidiabetics

Distribution Channel Insights:

•        Retail Pharmacies

•        Hospital Pharmacies

•        E-Commerce and Tele-Pharmacy

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=688&flag=C

Major Players Shaping the United States Diabetes Market

•        Novo Nordisk A/S – The United States diabetes market's leading company, with a broad portfolio including Ozempic, Rybelsus, Victoza, Awiqli, Fiasp, and Tresiba, supported by strong innovation in GLP-1 agonist and insulin therapies.

•        Lilly USA, LLC – Offers a strong diabetes therapy portfolio including Basaglar, Glyxambi, Humalog, Humulin, and Jardiance, backed by robust R&D capabilities and rapid commercial growth.

•        Sanofi – Maintains a strong presence in long-acting insulin therapies through products such as Toujeo, Lantus, Soliqua, Admelog, and Amaryl, supported by extensive global manufacturing and distribution capabilities.

•        AstraZeneca – Holds a strong position in oral diabetes therapies with products including Farxiga, Kombiglyze XR, and Onglyza.

•        Medtronic – A pioneer in closed-loop insulin delivery systems, offering the InPen Smart Insulin Pen and MiniMed 780G Insulin Pump.

•        Dexcom Inc. – An established player in continuous glucose monitoring technology, known for the Dexcom G7 and Stelo Glucose Biosensor.

Author IMARC Group

IMARC Group is a leading global management consulting firm providing comprehensive market research, feasibility studies, and strategic advisory services. The firm supports organizations worldwide in identifying growth opportunities, mitigating risks, and making informed business decisions across industries.

Contact Us

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302